title: FK-778 Astellas.
abstract: Astellas, under license from sanofi-aventis, is developing the immunosuppressant compound FK-778 as a potential treatment for organ transplantation. By February 2005, phase II trials were ongoing both in the US and in Europe.
authors.affiliation: Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI 48109, USA. makaplan@umich.edu
authors.forename: Mariana J
authors.initials: MJ
authors.lastname: Kaplan
mesh_terms: D000480:Alkynes; D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D004345:Drug Industry / Q000458:organization & administration; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007555:Isoxazoles; D009570:Nitriles / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use*; D016377:Organ Transplantation / Q000009:adverse effects
chemical_list: D000480:Alkynes; D007555:Isoxazoles; D009570:Nitriles; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide